To examine the impact of acquisition time on Lutetium-177 (177Lu) single-photon emission computed tomography (SPECT) images using Monte Carlo simulation. A gamma camera simulation based method was performed to produce SPECT images. The phantom modeled a NEMA IEC BODY including six spheres as tumors. After administration 7.4 GBq 177Lu, radioactivity concentrations tumor/liver at 6, 24, and 72 h ...

PurposePatient-specific dosimetry in MRT relies on quantitative imaging, pharmacokinetic assessment and absorbed dose calculation. The DosiTest project was initiated to evaluate the uncertainties associated with each step of clinical workflow through a virtual multicentric trial. This work presents generation simulated SPECT datasets based GATE Monte Carlo modelling its corresponding experiment...

objective(s):lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “no carrier added” (nca) 177lu. we have radiolabelled dota-conjugated peptide dota‐(tyr3)‐octreotate with nca 177lu (“nca-lutate”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. in this paper, we report on...

Prostate-specific membrane antigen (PSMA) continues to be an active biomarker for small-molecule PSMA-targeted imaging and therapeutic agents for prostate cancer and various non-prostatic tumors that are characterized by PSMA expression on their neovasculature. One of the challenges for small-molecule PSMA inhibitors with respect to delivering therapeutic payloads is their rapid renal clearance...

Although 177Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for "albumin hitchhiking" r...

BackgroundThis review and meta-analysis examined published evidence of peptide receptor radionuclide therapy (PRRT) re-treatment efficacy safety in patients with advanced neuroendocrine tumors (NETs).MethodsEmbase, MEDLINE, MEDLINE In-Progress, Cochrane CENTRAL were searched (database inception–present) to identify PRRT adults NETs previously treated 177Lu- and/or 90Y-PRRT. Progression-free sur...

Prostate-specific membrane antigen (PSMA) continues to be an active biomarker for small-molecule PSMA-targeted imaging and therapeutic agents for prostate cancer and various non-prostatic tumors that are characterized by PSMA expression on their neovasculature. One of the challenges for small-molecule PSMA inhibitors with respect to delivering therapeutic payloads is their rapid renal clearance...